|
|
||||||||
Original Research Communications |
| ABSTRACT |
|---|
|
|
|---|
Objective: We investigated whether altered eicosanoid production in preeclamptic women could be explained by the fatty acid composition of umbilical vessel walls and platelets.
Design: The fatty acid composition of maternal and umbilical platelets and of umbilical arteries and veins in 27 preeclamptic women and 24 normotensive women was determined. Between-group differences were analyzed with linear discriminant analysis, the Kruskal-Wallis test, or analysis of covariance with gestational age as the covariate.
Results: Platelets of preeclamptic women contained lower amounts of 20:5n-3 and a higher ratio of 20:4n-6 to 20:5n-3 than did platelets of normotensive women. Additionally, linear discriminant analysis revealed higher amounts of 20:4n-6 in platelets of preeclamptic women. Umbilical arteries and veins in preeclamptic women contained lower amounts of long-chain polyunsaturated fatty acids (PUFAs) of the n-3 series, n-6 long-chain PUFAs, and 20:3n-6 than did umbilical arteries and veins of normotensive women. Umbilical arteries also had lower amounts of 20:4n-6, higher amounts of 20:3n-9, and a higher ratio of 20:3n-9 to 20:4n-6.
Conclusions: Low amounts of long-chain n-3 and n-6 PUFAs in umbilical vessels of preeclamptic women with adequate n-6 status may indicate insufficient transplacental transfer of long-chain PUFAs. The low amounts of 20:4n-6, high amounts of 20:3n-9, and high ratio of 20:3n-9 to 20:4n-6 in umbilical arteries may unfavorably affect local prostacyclin production. Low amounts of 20:3n-6 in umbilical arteries and veins and low amounts of 20:5n-3 in maternal platelets may contribute to the dominance of eicosanoids derived from 20:4n-6.
Key Words: Preeclampsia fatty acids umbilical vessels platelets eicosanoids long-chain polyunsaturated fatty acids women pregnancy n-3 fatty acids n-6 fatty acids
| INTRODUCTION |
|---|
|
|
|---|
Long-chain PUFAs are fatty acids with
20 carbon atoms and
3 double bonds. They are derived from the parent essential fatty acids linoleic (18:2n-6) and
-linolenic (18:3n-3) acids by alternating desaturation and chain elongation (6). Long-chain PUFAs are structural components of membrane phospholipids and are precursors of eicosanoids (prostaglandins, thromboxanes, and leukotrienes). The quantitatively most important long-chain PUFA from 18:2n-6 is arachidonic acid (20:4n-6), whereas 18:3n-3 is converted into eicosapentaenoic (20:5n-3) and docosahexaenoic (22:6n-3) acids. The fatty acids 20:4n-6 and 20:5n-3 are precursors of TxA2 and TxA3 in platelets and of PGI2 and PGI3 in vascular endothelium, respectively. TxA2 is a potent vasoconstrictor and platelet aggregator, whereas TxA3 is less potent (7). PGI2 and PGI3 are equipotent vasodilators and inhibitors of platelet aggregation. The dietary intake of n-3 and n-6 fatty acids determines to a large extent the ratio of 20:4n-6 to 20:5n-3, and can thereby influence eicosanoid-mediated vasoactive effects. The present Western diet, characterized by a high intake of n-6 fatty acids (notably 18:2n-6) and a low intake of n-3 fatty acids (from 18:3n-3 and fish), may promote platelet aggregation and vasoconstriction (8).
Fetuses have a high long-chain PUFA requirement, eg, for development of the brain. It is widely recognized today that the fetal rate of long-chain PUFA synthesis from the parent essential fatty acids is insufficient to cover the fetus's long-chain PUFA needs (9). A maternal supply is therefore essential; insufficient fetal long-chain PUFA accrual may cause growth retardation and influence gestational age. For instance, prenatal long-chain PUFA status, notably that of 20:4n-6 and 22:6n-3, is related to birth weight (1012), head circumference (1316), and abdominal circumference (15) and 22:6n-3 is correlated with length of gestation (11). Studies have shown that umbilical wall 22:6n-3 concentrations correlate with weight, length, and head circumference at birth (16, 17). Fetal long-chain PUFA status seems marginal even under normal conditions because of the lower long-chain PUFA status in umbilical arteries than in umbilical veins (13). It is possible that abnormalities in maternal essential fatty acid status, in transplacental long-chain PUFA transport, or in essential fatty acid handling by the fetus accentuate the already low long-chain PUFA status of the umbilical arteries under normal conditions and thereby induce a local state of platelet aggregation and vasoconstriction.
In the present study, the fatty acid compositions of platelets, umbilical veins, and umbilical arteries of 27 preeclamptic women in Curaçao (Netherlands Antilles) were investigated. Results were compared with those in 24 normotensive, nonproteinuric, pregnant women.
| SUBJECTS AND METHODS |
|---|
|
|
|---|
90 mm Hg on
2 consecutive occasions
4 h apart (or as a diastolic blood pressure
110 mm Hg on any 1 occasion) in previously normotensive women in combination with proteinuria (one 24-h urine collection with a total protein excretion
0.3 g or 2 specimens of urine collected
4 h apart with
0.3 g albumin/L) (18). Twenty-four normotensive, nonproteinuric pregnant women served as control subjects. The characteristics of the study population are given in Table 1
|
Immediately after delivery, an
7-cm sample of the umbilical cord located at the most proximal site to the placenta was removed. The sample was immediately placed in an ice-cold 0.9%-NaCl solution until further processing. The 2 umbilical arteries and the umbilical vein were subsequently dissected from the surrounding tissue, thoroughly washed with an ice-cold 0.9%-NaCl solution, and dried on paper tissue. Umbilical arteries and veins were weighed and subsequently preserved by adding 2 mL methanol:HCl (5:1, by vol; 6 mol HCl/L) that contained 5 mg butylated hydroxytoluene.
All samples were stored at -20°C until transported on dry ice to the Central Laboratory for Clinical Chemistry (University Hospital Groningen). The long-chain fatty acid compositions of platelets, umbilical arteries, and umbilical veins were determined after transmethylation by capillary gas chromatography with split injection and flame-ionization detection (20). Results are expressed as relative amounts (mol%).
Statistics
Between-group comparisons of clinical characteristics were done with Student's t test at P < 0.05 (21). Differences in the fatty acid contents of umbilical arteries and veins were tested for both groups with the Kruskal-Wallis test at P < 0.05. In the analysis of between-group fatty acid differences, we first tested whether each of the individual fatty acids or ratios correlated with gestational age in preeclamptic women and control women separately by using the Spearman rank coefficient at P < 0.05. A finding of insignificant correlations in both subgroups was followed by use of the Kruskal-Wallis test at P < 0.05 for analysis of between-group differences. The finding of significant correlations for control women, preeclamptic women, or both was followed by analysis of covariance (ANCOVA) with gestational age as the covariate at P < 0.05 (21). Ratios of each of the fatty acids in umbilical arteries to umbilical veins were tested by using the same approach. Between-group comparisons of gestational age and fatty acid data were also investigated with linear discriminant analysis (21) by using the raw data. With stepwise variable selection, this method identified those variables that contributed to the discrimination between preeclamptic and control women.
| RESULTS |
|---|
|
|
|---|
Fatty acid compositions of maternal and umbilical cord platelets
The fatty acid compositions of maternal and umbilical cord platelets are presented in Table 2
. The following significant relations were found between the fatty acids and gestational age. There were positive relations with gestational age for 18:1n-9, total n-9 fatty acids, and monounsaturated fatty acids (MUFAs) in maternal platelets of control women and for 20:3n-6 in maternal platelets of preeclamptic women. There were negative relations with gestational age for 18:1n-9, total n-9 fatty acids, and MUFAs in maternal platelets of preeclamptic women. In umbilical platelets of preeclamptic women there were positive relations with gestational age for 18:0, 22:6n-3, 20:4n-6, 22:5n-6, total n-6 fatty acids, long-chain n-6 PUFAs, long-chain n-3 and n-6 PUFAs, saturated fatty acids (SFAs), PUFAs, and the ratios of 20:3n-6 to 18:2n-6, 20:4n-6 to 20:5n-3, and 22:6n-3 to 20:5n-3. In umbilical platelets of preeclamptic women there were negative relations with gestational age for 18:3n-3, 20:5n-3, 18:2n-6, 20:2n-6, 18:1n-9, total n-9 fatty acids, and MUFAs.
|
Fatty acid compositions of umbilical venous and arterial vessels
The fatty acid compositions of umbilical veins and arteries are presented in Table 3
. The following significant correlations with gestational age were found. Amounts of 22:6n-3 and 22:5n-6 in umbilical veins and amounts of 18:3n-3 in umbilical arteries were positively correlated with gestational age in control women, whereas amounts of 22:4n-6 in umbilical veins and the ratio of 20:3n-6 to 18:2n-6 in umbilical arteries were positively correlated with gestational age in preeclamptic women. 18:1n-9, total n-9 fatty acids, MUFAs, and the ratio of 20:3n-9 to 20:4n-6 in umbilical veins and amounts of 18:1n-9 and MUFAs in umbilical arteries were negatively correlated with gestational age in preeclamptic women.
|
Amounts of 22:5n - 3, total n-3 fatty acids, long-chain n-3 PUFAs, 20:3n-6, total n-6 fatty acids, long-chain n-6 PUFAs, long-chain n-3 and n-6 PUFAs, and PUFAs were lower in umbilical arteries and veins of preeclamptic women than in control women. In addition, 20:5n-3, 22:6n-3, 20:4n-6, and 22:4n-6 were lower and 20:3n-9 and total n-9 fatty acids were higher in umbilical arteries of preeclamptic women than in control women; 16:0 was higher in umbilical veins of preeclamptic women than in control women. Ratios of 22:5n-6 to 22:4n-6 were higher and ratios of 22:6n-3 to 22:5n-6 and of n-3 + n-6 to n-7 + n-9 fatty acids were lower in umbilical arteries and veins of preeclamptic women than in control women. The ratio of 20:3n-9 to 20:4n-6 was higher in umbilical arteries of preeclamptic women than in control women, whereas the ratio of 20:3n-6 to 18:2n-6 was lower and that of 20:4n-6 to 22:6n-3 was higher in umbilical veins of preeclamptic women than in control women. Only the umbilical arteryto-vein ratio of 18:2n-6 was lower in preeclamptic women than in control women.
Linear discriminant analysis
Linear discriminant analysis revealed that gestational age and amounts of 20:5n-3, 22:4n-6, and 22:5n-3 contributed to the discrimination between preeclamptic and control women for umbilical artery fatty acids. For umbilical vein fatty acids these variables were gestational age and amounts of 22:4n-6, 20:5n-3, 20:3n-6, 22:5n-3, and 22:6n-3; for maternal platelet fatty acids they were gestational age and amounts of 22:5n-6 and 20:4n-6; and for umbilical platelet fatty acids they were gestational age and amounts of 20:2n-6.
| DISCUSSION |
|---|
|
|
|---|
The lower long-chain n-3 and n-6 PUFA status of umbilical arteries especially may reflect impaired fetal long-chain PUFA accrual in preeclampsia, with insufficient amounts of long-chain PUFAs remaining for incorporation into the fetal tissues located most distal from the placental supply. Insufficient fetal long-chain PUFA deposition derives, theoretically, from abnormal fetal handling of essential fatty acids or an insufficient fetal long-chain PUFA supply. An insufficient supply may be the result of marginal maternal long-chain PUFA status, insufficient transplacental transport, or both. From a percentage point of view, the most striking abnormality in preeclampsia seemed to be the lower amounts of long-chain n-3 PUFAs in both umbilical arteries (-23%; Table 3
) and umbilical veins (-21%). The quantitatively most important long-chain n-3 PUFA in these compartments is 22:6n-3. Part of the difference in 22:6n-3 between preeclamptic and control women may be explained by the gestational age dependency of 22:6n-3. The marginal 22:6n-3 status in umbilical arteries and veins of preeclamptic women was confirmed by the lower ratio of 22:6n-3 to 22:5n-6 and higher ratio of 22:5n-6 to 22:4n-6, both of which are indicators of functional 22:6n-3 deficiency (23). Note that the dietary intake of n-3 fatty acids (8) from vegetable oils and fish in many Western societies, including Curaçao (24), is low compared with the intake of the competing essential fatty acids of the n-6 series (notably 18:2n-6). On the other hand, amounts of 20:4n-6 in umbilical arteries (-18%) and umbilical veins (-9%; NS) were also low. Lower amounts of 20:4n-6 may be of special interest because this finding is related to lower birth weight (12). Low fetal n-3 and n-6 status in mothers with adequate n-6 status argues in favor of insufficient transplacental transport. Future maternal long-chain PUFA supplementation studies may indicate whether fetal long-chain PUFA shortages are indeed causally related to the pathogenesis of preeclampsia.
Interpreting our findings in terms of eicosanoid production is difficult because our fatty acid data were derived from whole tissue, not from those subcellular compartments and lipid classes that exclusively add to the local production of eicosanoids. Moreover, many factors influence the subsequent relation between eicosanoid production and the long-chain PUFA contents of the subcellular phospholipids that actually serve as eicosanoid precursors. However, preeclamptic women did have lower platelet contents of the precursor of TxA3 (ie, 20:5n-3) together with unaltered contents of the precursor of TxA2 (ie, 20:4n-6) and a higher ratio of 20:4n-6 to 20:5n-3 than control women (Table 2
). Higher amounts of 20:4n-6 in platelets of preeclamptic women became apparent from the linear discriminant analysis. Taken together, these results may be consistent with TxA2 dominance, but it must be pointed out that amounts of 20:5n-3 in platelets were extremely low compared with those of 20:4n-6 and that the encountered differences were small.
Fatty acid differences between preeclamptic and control women in the umbilical vessels (Table 3
) seemed more pronounced than the differences in platelets. This result may be in line with the finding that umbilical arteries of preeclamptic women produce less prostacyclin (25) than umbilical arteries of normotensive women and that prostacyclin production is inversely related to the ratio of 20:3n-9 to 20:4n-6 in umbilical arteries (26). Umbilical arteries in our study had lower contents of 20:4n-6, higher contents of 20:3n-9, and a higher ratio of 20:3n-9 to 20:4n-6 than did umbilical veins. Crawford et al (14) found that umbilical arteries of babies with the lowest birth weights had the highest 20:3n-9 contents. It is as yet unclear whether the 4 times higher 20:3n-9 content in umbilical arteries than in umbilical veins reflects a local essential fatty acid deficiency. Classically, essential fatty acid deficiency results in the production of 20:3n-9 from 18:1n-9 by
6 desaturation and chain elongation because of the local lack of the preferred
6 desaturase substrates 18:3n-3 and 18:2n-6. Umbilical arteries and veins do not seem to differ much, however, in the contents of these substrates, which may argue in favor of a derivation of 20:3n-9 from the maternal circulation. Feeding rats with a 20:3n-9-rich oil was found to cause incorporation of this fatty acid into various plasma lipid classes and into the phospholipids of all investigated organs (27). It is possible that 20:3n-9 undergoes similar preferential transplacental transport as long-chain PUFAs of the n-3 and n-6 series by the poorly understood process of biomagnification (10), but is subsequently deposited downstream as a second-choice long-chain PUFA because of the local limited availability of long-chain PUFAs of the n-3 and n-6 series.
The lower amount of 20:3n-6 in umbilical veins and arteries, the lower ratio of 20:3n-6 to 18:2n-6 in umbilical veins (Table 3
), and the lower amount of 20:3n-6 in umbilical veins identified by linear discriminant analysis in preeclamptic women might be consistent with lower
6 desaturation activity because neither 18:3n-6 (the intermediate
6 desaturase product in the conversion of 18:2n-6 to 20:3n-6) nor 20:3n-6 belong to the usual arsenal of dietary fatty acids. Dihomo-
-linolenic acid (20:3n-6) is the precursor of eicosanoids of the 1-series (28). These eicosanoids share much of the properties of those of the 3-series (ie, from 20:5n-3) and may therefore counteract the vasoconstrictive and platelet-aggregating effects of eicosanoids of the 2-series (from 20:4n-6). Lower amounts of 20:3n-6 and a lower ratio of 20:3n-6 to 18:2n-6 also suggest that the production of 20:3n-9 is unlikely to be by synthesis from 18:1n-9 via
6 desaturation.
In conclusion, preeclampsia is characterized by low amounts of long-chain PUFAs of the n-3 and n-6 series in umbilical veins and most notably in umbilical arteries. The underlying cause may be insufficient transplacental transfer of long-chain PUFAs because the women had normal n-6 status. Platelets of preeclamptic women had lower amounts of 20:5n-3 and a higher ratio of 20:4n-6 to 20:5n-3. These differences, however, were small and it is therefore questionable whether they contributed much to the TxA2 dominance. Umbilical arteries of preeclamptic women had lower amounts of 20:4n-6, higher amounts of 20:3n-9, and a higher ratio of 20:3n-9 to 20:4n-6, which may unfavorably affect local prostacyclin production and cause other adverse effects related to 20:3n-9. It is possible that the high amounts of 20:3n-9 in umbilical arteries were not derived merely from local synthesis, but originated from the maternal circulation. Umbilical veins and arteries of preeclamptic women also had low amounts of 20:3n-6, which together with low 20:5n-3 in maternal platelets may contribute to the dominance of 20:4n-6-derived eicosanoids in preeclampsia.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
2 Supported by the Netherlands Antilles Foundation for Clinical Higher Education (NASKHO).
3 Address reprint requests to FV Velzing-Aarts, c/o FAJ Muskiet, Central Laboratory for Clinical Chemistry, CMC-V, Y1.147, University Hospital Groningen, Hanzeplein 1, 9713 GZ Groningen, Netherlands. E-mail: f.a.j.muskiet{at}lab.azg.nl.
| REFERENCES |
|---|
|
|
|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |